Liver Enzymes on Cycle: ALT, AST, and When to Pause

ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are enzymes released when liver cells — and, to a lesser extent, muscle tissue — are stressed or damaged. On cycle, the first question is always: orals in the stack? Methylated oral AAS are hepatotoxic by design; injectables alone rarely produce dramatic enzyme spikes unless something else is contributing.

17-alpha-alkylated orals (methylated steroids, many designer orals) pass through the liver on first pass and predictably raise ALT and AST. Mild elevations on moderate doses are common; the question is magnitude, trajectory, and symptoms — not whether enzymes moved at all. Stacking multiple orals, running orals for 8+ weeks, or combining orals with other hepatotoxic drugs (certain NSAIDs, high-dose acetaminophen, heavy alcohol) compounds risk nonlinearly.

• Draw liver enzymes at least once mid-oral run — earlier if dose is high or history of sensitivity
• Rising enzymes week over week matter more than a single static elevation
• Jaundice, dark urine, persistent right-upper-quadrant pain, or unexplained nausea are clinical red flags regardless of numbers

Testosterone and most injectable AAS are not first-pass liver toxins in the same way orals are. If ALT and AST are elevated on an injectable-only stack, look elsewhere first: a heavy training session within 48–72 hours (especially eccentric-heavy work), significant muscle damage, dehydration, viral illness, or medications. AST tends to rise more with muscle breakdown than ALT; an AST-predominant spike after leg day is a different conversation than both enzymes climbing steadily on week 4 of an oral.

Roiders Club optimal targets for ALT and AST reflect health on a very minimal cycle — not the lab's wide reference range. Values in the caution band warrant retesting under controlled conditions (no heavy training for 3 days, normal hydration, no alcohol) before changing protocol. Strict-threshold flags mean stop orals, remove other hepatotoxic inputs, and involve a clinician if symptoms accompany the rise or retest confirms the trend.

TUDCA, NAC, and milk thistle are commonly discussed as liver support. Evidence for TUDCA reducing oral-induced enzyme rises is real but not a license to extend toxic oral runs. Support compounds may blunt enzyme peaks — they do not eliminate hepatotoxicity. If enzymes climb despite support, the answer is dose reduction or cessation, not more supplements.

• Enzymes above caution band on retest under controlled draw conditions
• Any strict-threshold flag with or without symptoms
• Symptoms of liver dysfunction even if enzymes look "acceptable"
• Week-over-week rise without a non-liver explanation

Liver enzymes on cycle are a trend and context problem. Orals will move them; injectables usually should not dramatically. Train timing, hydration, and draw consistency matter. Retest before panicking, escalate when trends or symptoms demand it, and treat strict flags as a pause signal — not a number to rationalize away.